Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
about
p53 as a Regulator of Lipid Metabolism in CancerA covalent PIN1 inhibitor selectively targets cancer cells by a dual mechanism of action.Bronchoalveolar Lavage Proteomics in Patients with Suspected Lung CancerIdentification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer.Inhibiting the system xC-/glutathione axis selectively targets cancers with mutant-p53 accumulationTp53 and its potential therapeutic role as a target in bladder cancer.Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidanceTargeting mutant p53 through the mevalonate pathway.Targeting mutant p53 in cancer: a long road to precision therapy.Reviving the guardian of the genome: Small molecule activators of p53.Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy.Molecularly targeted therapies for p53-mutant cancers.Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.Multisite aggregation of p53 and implications for drug rescue.Mutant p53-Nrf2 axis regulates the proteasome machinery in cancerMulti-omics reveals global effects of mutant p53 gain-of-function.Transcriptional Regulation by Nrf2.Inhibiting system xC- and glutathione biosynthesis - a potential Achilles' heel in mutant-p53 cancers.Mutant p53 partners in crime.Proteome Stability as a Key Factor of Genome Integrity.P53 at the start of the 21st century: lessons from elephants.Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas.Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1.Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation.Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.Gain-of-function mutant p53 activates small GTPase Rac1 through SUMOylation to promote tumor progression.p53 gain-of-function mutations increase Cdc7-dependent replication initiation.Proteomic identification of ERP29 as a key chemoresistant factor activated by the aggregating p53 mutant Arg282Trp.Knockdown of TP53 in ASXL1 negative background rescues apoptotic phenotype of human hematopoietic stem and progenitor cells but without overt malignant transformation.Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.New therapeutic strategies to treat human cancers expressing mutant p53 proteins.Proteasome dysregulation in human cancer: implications for clinical therapies.p53 mutations promote proteasomal activity.Potential therapeutic targets of TP53 gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer.Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells.Complexes formed by mutant p53 and their roles in breast cancer.Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target.Oncogenic addiction to high 26S proteasome level.O-GlcNAcylation Signal Mediates Proteasome Inhibitor Resistance in Cancer Cells by Stabilizing NRF1Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a "dominant-positive" mechanism
P2860
Q28079393-F617BED9-3EB4-4DB1-BFC8-24F499A5D357Q33804626-32C87616-643D-4E1E-A15D-C369974C15FBQ37627629-176519ED-D9D3-480D-972B-AA357864C0EBQ37656224-31211514-F8BB-4E63-A85D-5B82C7D4BC5CQ37736385-9645B454-48EC-41B5-840E-4AEC1A021D34Q38436074-720EAEA1-FB57-4DB3-A3CB-5BD33652E7D5Q38739048-B2727D8D-CF5D-438F-A085-BAF16F76CA90Q38991977-5A8BDE08-18F7-4E02-9921-A87D84B2E521Q38997351-51182FFA-FA90-4860-AF6A-5EE108BC363EQ39205536-00DECF89-569E-45B3-8F82-493C803645A8Q39229004-FBA7E3F9-5622-491F-A3E2-3FC049B023D7Q39393193-37AD8CE0-423E-4EA8-9BA1-D8B788CE502AQ41291592-121853CF-3EC7-4897-B8A7-9228686D91E6Q41677793-9A61235C-7FAB-434A-BAD6-ECA55CE10FE1Q42325001-101EDA65-9EC9-421D-9469-450542489B2EQ42359639-07059E94-8D37-484F-A5EA-1A25EA9E0DD1Q42514932-CE2F20DC-76D3-4DA7-A814-6A29CB39789AQ46277999-58461428-71DA-4BFF-AFEA-2EDD3CD4F58FQ47107350-61AF2CE8-91E8-4710-AB8B-47BD64A64B7BQ47113405-E85E8ABF-4C4D-4108-9EDD-3ED10B4CBE9CQ47121630-131D0F97-C881-4E38-8DF9-0067EB231B6DQ47133172-93988F52-317E-4C00-AC8C-B7655F162E85Q47262684-D46B58E6-5F70-4E2A-9178-25915376C730Q47676673-E0EF19EE-6408-4411-9CDA-1C8B90E8FBD2Q47742599-6F785376-6DB9-4C35-AB11-6C6FE2AF80D5Q47744553-608CEB83-C3E4-41AD-A2DF-8292F850C5FFQ48100871-EA375DFD-74C4-4C96-AB46-34E2B02F4335Q48112435-8F72B736-E750-40EB-B933-2C25747FF6A3Q49248026-5201CE3F-7F7C-4AC7-BAB3-AF7F7D3CBE44Q49937490-2EEFDA58-1542-413F-8F5E-3347D5CA6393Q49962911-BECC0030-A130-49D1-AE07-99A6036A7953Q50077966-A1A4F0CC-4F9D-4A92-A624-DD52FD8E0492Q51613253-BA348C6C-C1C7-4A7F-94DF-87EACC6BD808Q52584348-AE7168C6-6A12-456E-8A23-5B77E48868B7Q55281959-3F133816-3E9A-4E09-95EB-18ECB6FB68E4Q55333537-0D6DECD7-D166-4363-9EE5-1CC4EF40E604Q55515721-5226DA85-8C2A-4C0E-9E6F-31D0694F2FC5Q55559653-C448EA1E-C49E-4AC4-BD20-D5EC3AD1025CQ58778244-BDF338FB-36D2-4844-B06A-C99B45E40517Q58789576-8FE91295-616E-40A0-B119-3F1620B7BBEB
P2860
Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh-hant
name
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@en
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@nl
type
label
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@en
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@nl
prefLabel
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@en
Proteasome machinery is instru ...... 53 missense mutants in cancer.
@nl
P2093
P2860
P50
P356
P1433
P1476
Proteasome machinery is instru ...... p53 missense mutants in cancer
@en
P2093
Eleonora Ingallina
Jacek R Wiśniewski
Katarzyna Gaweda-Walerych
Katarzyna Rajkowska
Marco J Morelli
Vincenzo Eterno
P2860
P2888
P304
P356
10.1038/NCB3380
P50
P577
2016-06-27T00:00:00Z